Leerink Partners Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA)

Equities research analysts at Leerink Partners began coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report issued on Tuesday, Briefing.com reports. The brokerage set an “outperform” rating and a $44.00 price target on the stock. Leerink Partners’ target price indicates a potential upside of 69.88% from the company’s current price.

Several other equities research analysts have also recently commented on ORKA. TD Cowen initiated coverage on Oruka Therapeutics in a research note on Monday. They set a “buy” rating for the company. Lifesci Capital began coverage on shares of Oruka Therapeutics in a research report on Monday. They set an “outperform” rating and a $41.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of Oruka Therapeutics in a research note on Friday. They issued a “buy” rating and a $40.00 target price for the company. Finally, Wedbush initiated coverage on shares of Oruka Therapeutics in a research note on Wednesday, September 4th. They set an “outperform” rating and a $40.00 price target on the stock. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $41.25.

Oruka Therapeutics Trading Up 4.1 %

Shares of ORKA stock opened at $25.90 on Tuesday. Oruka Therapeutics has a 52-week low of $18.72 and a 52-week high of $53.88.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.